Type 2 diabetes is closely linked to obesity, which in turn, increases the risk for cardiovascular diseases (which includes mainly heart disease and stroke), muscle and bone diseases; and cancers. Obesity-related cancers include breast, endometrial, ovarian, colorectal, pancreatic, renal, liver and gallbladder cancer. [Lancet2008;371(9612):569–578]
Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.
The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.